Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC

Margaret Gatti-Mays • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Prostate Cancer SYNC-T

Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, discusses findings from a study of SYNC-T therapy, a personalized cancer vaccine with intratumoral immunotherapy explored in patients with metastatic castration-resistant prostate cancer (mCRPC). SYNC-T therapy was well tolerated and achieved an 87% overall response rate in patients with mCRPC. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Margaret Gatti-Mays

Strategies to overcome barriers in cancer vaccine efficacy
1:32
Strategies to overcome barriers in cancer vaccine efficacy
Margaret Gatti-Mays • 1 Jun 2025
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
1:28
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
Margaret Gatti-Mays • 1 Jun 2025
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer
1:40
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer
Margaret Gatti-Mays • 1 Jun 2025
TGFβi NKs with naxitamab and gemcitabine for GD2+ breast cancer
2:45
TGFβi NKs with naxitamab and gemcitabine for GD2+ breast cancer
Margaret Gatti-Mays • 12 Dec 2024

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals